Drug Profile
DTX 101
Alternative Names: AAVrh10FIX; DTX101; Wild-type FIX AAVrh10 vectorLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Dimension Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia B
Most Recent Events
- 07 Nov 2017 Dimension Therapeutics has been acquired by Ultragenyx Pharmaceutical
- 10 May 2017 Dimension Therapeutics terminates a phase I/II trial in Haemophilia B in USA and Bulgaria as the analysis did not meet the company's minimum target product profile for continued development or future commercialisation (Parenteral) (NCT02618915)
- 10 May 2017 Discontinued - Phase-I/II for Haemophilia B in USA and Bulgaria (Parenteral)